Frontiers in Immunology (Jul 2022)
Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis
- María B. Arriaga,
- María B. Arriaga,
- María B. Arriaga,
- María B. Arriaga,
- Farina Karim,
- Artur T.L. Queiroz,
- Artur T.L. Queiroz,
- Mariana Araújo-Pereira,
- Mariana Araújo-Pereira,
- Mariana Araújo-Pereira,
- Beatriz Barreto-Duarte,
- Beatriz Barreto-Duarte,
- Beatriz Barreto-Duarte,
- Caio Sales,
- Caio Sales,
- Mahomed-Yunus S. Moosa,
- Matilda Mazibuko,
- Ginger L. Milne,
- Fernanda Maruri,
- Carlos Henrique Serezani,
- John R. Koethe,
- Marina C. Figueiredo,
- Afrânio L. Kritski,
- Marcelo Cordeiro-Santos,
- Marcelo Cordeiro-Santos,
- Marcelo Cordeiro-Santos,
- Valeria C. Rolla,
- Timothy R. Sterling,
- Alasdair Leslie,
- Alasdair Leslie,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- Bruno B. Andrade,
- the RePORT Brazil and South Africa consortia,
- Alice M. S. Andrade,
- Michael S. Rocha,
- Vanessa Nascimento,
- Juan M. Cubillos-Angulo,
- Hayna Malta-Santos,
- Jéssica Rebouças-Silva,
- Sayonara M. Viana,
- Saulo R. N. Santos,
- André Ramos,
- Alysson G. Costa,
- Jaquelane Silva,
- Jamile G. de Oliveira, Secretaria,
- Aline Benjamin,
- Adriano Gomes-Silva,
- Flavia M. Sant’Anna,
- Francine P. Ignácio,
- Maria Cristina Lourenço,
- Elisangela C. Silva,
- Adriana S. R. Moreira,
- Mayla Mello
Affiliations
- María B. Arriaga
- Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- María B. Arriaga
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- María B. Arriaga
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil
- María B. Arriaga
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
- Farina Karim
- Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
- Artur T.L. Queiroz
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- Artur T.L. Queiroz
- Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Mariana Araújo-Pereira
- Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Mariana Araújo-Pereira
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- Mariana Araújo-Pereira
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil
- Beatriz Barreto-Duarte
- Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Beatriz Barreto-Duarte
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- Beatriz Barreto-Duarte
- Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil
- Caio Sales
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- Caio Sales
- Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil
- Mahomed-Yunus S. Moosa
- Africa Health Research Institute, Durban, South Africa
- Matilda Mazibuko
- Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
- Ginger L. Milne
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Fernanda Maruri
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Carlos Henrique Serezani
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- John R. Koethe
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Marina C. Figueiredo
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Afrânio L. Kritski
- 1Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- Marcelo Cordeiro-Santos
- 2Fundação Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil
- Marcelo Cordeiro-Santos
- 3Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil
- Marcelo Cordeiro-Santos
- 4Universidade Federal do Amazonas, Manaus, Brazil
- Valeria C. Rolla
- 5Laboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil
- Timothy R. Sterling
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Alasdair Leslie
- Africa Health Research Institute, Durban, South Africa
- Alasdair Leslie
- 6Division of Infection and Immunity, University College London, London, United Kingdom
- Bruno B. Andrade
- Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
- Bruno B. Andrade
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil
- Bruno B. Andrade
- Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil
- Bruno B. Andrade
- Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil
- Bruno B. Andrade
- 0Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States
- Bruno B. Andrade
- 7Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil
- the RePORT Brazil and South Africa consortia
- Alice M. S. Andrade
- Michael S. Rocha
- Vanessa Nascimento
- Juan M. Cubillos-Angulo
- Hayna Malta-Santos
- Jéssica Rebouças-Silva
- Sayonara M. Viana
- Saulo R. N. Santos
- André Ramos
- Alysson G. Costa
- Jaquelane Silva
- Jamile G. de Oliveira, Secretaria
- Aline Benjamin
- Adriano Gomes-Silva
- Flavia M. Sant’Anna
- Francine P. Ignácio
- Maria Cristina Lourenço
- Elisangela C. Silva
- Adriana S. R. Moreira
- Mayla Mello
- DOI
- https://doi.org/10.3389/fimmu.2022.919802
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundOxidized lipid mediators such as eicosanoids play a central role in the inflammatory response associated with tuberculosis (TB) pathogenesis. Diabetes mellitus (DM) leads to marked changes in lipid mediators in persons with TB. However, the associations between diabetes-related changes in lipid mediators and clearance of M. tuberculosis (Mtb) among persons on anti-TB treatment (ATT) are unknown. Quantification of urinary eicosanoid metabolites can provide insights into the circulating lipid mediators involved in Mtb immune responses.MethodsWe conducted a multi-site prospective observational study among adults with drug-sensitive pulmonary TB and controls without active TB; both groups had sub-groups with or without dysglycemia at baseline. Participants were enrolled from RePORT-Brazil (Salvador site) and RePORT-South Africa (Durban site) and stratified according to TB status and baseline glycated hemoglobin levels: a) TB-dysglycemia (n=69); b) TB-normoglycemia (n=64); c) non-TB/dysglycemia (n=31); d) non-TB/non-dysglycemia (n=29). We evaluated the following urinary eicosanoid metabolites: 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (major urinary metabolite of prostaglandin E2, PGE-M), tetranor-PGE1 (metabolite of PGE2, TN-E), 9α-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (metabolite of PGD2, PGD-M), 11-dehydro-thromboxane B2 (11dTxB2), 2,3-dinor-6-keto-PGF1α (prostaglandin I metabolite, PGI-M), and leukotriene E4 (LTE4). Comparisons between the study groups were performed at three time points: before ATT and 2 and 6 months after initiating therapy.ResultsPGE-M and LTE4 values were consistently higher at all three time-points in the TB-dysglycemia group compared to the other groups (p<0.001). In addition, there was a significant decrease in PGI-M and LTE4 levels from baseline to month 6 in the TB-dysglycemia and TB-normoglycemia groups. Finally, TB-dysglycemia was independently associated with increased concentrations of PGD-M, PGI-M, and LTE4 at baseline in a multivariable model adjusting for age, sex, BMI, and study site. These associations were not affected by HIV status.ConclusionThe urinary eicosanoid metabolite profile was associated with TB-dysglycemia before and during ATT. These observations can help identify the mechanisms involved in the pathogenesis of TB-dysglycemia, and potential biomarkers of TB treatment outcomes, including among persons with dysglycemia.
Keywords
- dysglycemia
- Mycobacterium tuberculosis
- urinary eicosanoids
- lipid mediators
- anti-tuberculosis treatment